MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
Healthcare
$53.42 -1.54%
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
52W Low $9.43High $45.85
Volume 0.73M
Average 0.65M
MBX Pre-Tax Margin
Income before tax as a percentage of revenue.
No reported Pre-Tax Margin figures are available to summarize.
Pre-Tax Margin history
Percent of revenue · from the income statement
No Pre-Tax Margin data reported for this period type.
Pre-Tax Margin vs competitors
How MBX compares with its peers on the latest reported figures
MBX Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 3766.2% | — | +5159.6 pp | |
| LTM Sep 2026 | 22.4% | +57.0 pp | +1099.6 pp | |
| LTM Mar 2026 | 3.8% | +25.2 pp | +87.3 pp | |
| LTM Sep 2026 | -68.5% | +41.6 pp | +662.9 pp | |
| LTM Mar 2026 | -253002.8% | +201602.2 pp | -341389.6 pp | |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding MBX) | 3.8% | +49.3 pp | +662.9 pp | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.